Sagimet Biosciences (SGMT) Leerink Global Healthcare Conference 2026 summary

Strategic focus and clinical development

• Emphasis on FASN inhibition as a therapeutic approach for MASH, acne, and certain solid tumors, with Denifanstat as the lead candidate.

• Combination therapy with Resmetirom targets the underserved F4 cirrhotic MASH population, supported by preclinical and clinical data showing improved inflammation and fibrosis outcomes.

• Phase II study for the MASH combination is planned to start in the second half of 2024, with a non-invasive design pending FDA discussions.

• Next-generation FASN inhibitor is in Phase I, with Phase II proof-of-concept results expected in the second half of 2025.

• Strategic partnership with Teva API secures IP rights for 20 Resmetirom polymorphs, enabling fixed-dose combination development.

Clinical data and regulatory pathways

• Phase II data in F2/F3 MASH patients showed a 36% delta over placebo and 30% delta for two-stage improvement; digital pathology confirmed regression in F4 patients.

• Combination of Denifanstat and Resmetirom leverages complementary mechanisms, with both molecules suitable for fixed-dose oral administration.

• Bridging studies will ensure bioequivalence when transitioning between different Resmetirom forms in clinical development.

• Phase I data for the combination will be presented at EASL, with a fixed-dose, non-weight-based regimen planned.

• Regulatory strategy aims for non-invasive endpoints in both Phase II and future Phase III studies, aligning with evolving FDA standards.

Acne program and commercial outlook

• Chinese partner completed successful Phase II and III trials for Denifanstat in acne, with NDA accepted and approval expected late 2024 or early 2025.

• U.S. development may leverage Chinese data, with a pre-IND meeting held and a focus on next-gen molecule TVB-3567, currently in Phase I.

• Phase II for TVB-3567 in acne is planned for late 2024, with a 12-week study to determine dosing.

• Commercialization of acne indication is feasible independently or with a partner, with potential to expedite development by 18–24 months if Denifanstat is advanced.

• Cash runway of $125 million as of Q3 2023 supports operations through 2027, covering key milestones in both MASH and acne programs.